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Gene suppression via U1 small nuclear RNA interference (U1i) is considered to be one of the most attrac-
tive approaches, and takes the place of general antisense, RNA interference (RNAi), and anti-micro RNA
machineries. Since the U1i can be induced by short oligonucleotides (ONs), namely U1 adaptors consist-
ing of a ‘target domain’ and a ‘U1 domain’, we prepared adaptor ONs using 20-modiﬁed-40-thionucleo-
sides developed by our group, and evaluated their U1i activity. As a result, the desired gene
suppression via U1i was observed in ONs prepared as a combination of 20-ﬂuoro-40-thionucleoside and
20-ﬂuoronucleoside units as well as only 20-ﬂuoronucleoside units, while those prepared as combination
of 20-OMe nucleoside/20-OMe-40-thionucleoside and 20-ﬂuoronucleoside units did not show signiﬁcant
activity. Measurement of Tm values indicated that a higher hybridization ability of adaptor ONs with com-
plementary RNA is one of the important factors to show potent U1i activity.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Nucleic acid-based therapeutics using antisense, short-
interfering RNA (siRNA), and anti-micro RNA molecules are inten-
sely interested in new generation of drug development.1 Thus far, a
number of chemically-modiﬁed oligonucleotides (ONs) have been
developed toward not only in vitro, but also in vivo utility, and
their activity of gene suppression has been evaluated.2–4 To expand
the possibilities of nucleic acids-based therapeutics, however,
development of a new approach to gene suppression along with
above-mentioned machineries is required. Gene silencing machi-
nary using U1 small nuclear RNA (U1 snRNA), a component of U1
small nuclear ribonucleoprotein (snRNP), has been considered to
be one of the most promising prospective approaches. The primary
function of U1 snRNA is recognition of the 50 splice site sequence
during pre-mRNA splicing by base pairing in its 50 end. In addition,
U1 snRNA can suppress the gene expression via sequence-speciﬁc
binding upstream of the poly(A) signal of pre-mRNA, which is
termed U1 snRNA interference (U1i).5,6 Beckley et al. have con-structed expression plasmids that code 50-end-mutated U1 snR-
NAs, including complementary sequences against exogenous and
endogenous genes, and succeeded to suppress the target genes
upon transfection of the constructed plasmids into cultured cells.7,8
Although their approach seems to be attractive and effective for
gene suppression, no further advance toward nucleic acid-based
therapeutics was reported, because of the inconvenience of pre-
pareing custom U1i targeting plasmids. However, Goraczniak
et al. have recently succeeded to induce U1i using short ONs, U1
adaptors.9 The U1 adaptors consists of two domains: a ‘target do-
main’ designed to base pair to the target gene’s pre-mRNA in the
30-terminal exon, and a ‘U1 domain’ that recruites U1 snRNP to
the target pre-mRNA. In addition, the adaptors consist of 20-OMeR-
NA and locked nucleic acid (LNA), which have a higher hybridiza-
tion ability with the target RNA sequences. Accordingly, U1
snRNP was recruited on the pre-mRNA near the poly(A) signal with
assistance of the adaptors to suppress gene expression. Since this
phenomenon can be induced by readily available short ONs, U1i
caused by the U1 adaptors may be an alternative approach to effec-
tive and sequence-speciﬁc gene suppression.
Meanwhile, we have been working on a project to develop
chemically-modiﬁed ONs, which can be applicable to aptamer,
antisense and RNAi machineries. Thus far, we have reported the
synthesis of 40-thioRNA10 and 40-thioDNA,11 which possess a sulfur
atom instead of sugar ring oxygen, and their utility toward the
applications of nucleic acid-based therapeutics.12–16 Furthermore,
Figure 2. Preparation of reporter assay system. (A) Structures and sequences of
luciferase reporter plasmids. Details were described in the Section 3. (B) Recruit-
ment of U1snRNP by U1 adaptor.
Figure 3. Luciferase activity upon transfection of a series of WT and MT plasmids.
Each ﬁreﬂy luciferase activity is normalized to the cotransfected Renilla luciferase
activity, and relative luciferase activity is shown based on the activity of pGL3-C.
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oro-40-thioRNA (20-F-40-thioRNA) and 20-OMe-40-thioRNA, which
have a hybrid chemical modiﬁcation based on 20-modiﬁed ONs
and 40-thioRNA (Fig. 1). In their hybridization with a complemen-
tary RNA, 20-F-40-thioRNA showed the highest Tm value among
the ONs evaluated. On the other hand, 20-OMe-40-thioRNA showed
the highest stability against nuclease digestion in a comprehensive
comparison. Concerning 20-OMe-40-thioRNA, we showed that this
modiﬁcation induced potent and long-term RNAi activity com-
pared with siRNAs modiﬁed with 40-thioRNA and 20-OMeRNA.18
These preferable properties of 20-modiﬁed-40-thioRNAs prompted
us to evaluate whether the ONs containing 20-OMeRNA and 20-F-
40-thioRNA act as U1 adaptors instead of those containing 20-
OMeRNA and LNA.
In this paper, we describe the synthesis of adaptor ONs using 20-
modiﬁed-40-thionucleosides,19 components of 20-modiﬁed-40-
thioRNAs, and evaluated their gene suppression activity via U1i
machinery.
2. Results and discussion
We ﬁrst constructed reporter assay system to evaluate U1i
activity of the U1 adaptors. As shown in Figure 2A, a plasmid, orig-
inating from pGL3-C ﬁreﬂy luciferase expression plasmid, was pre-
pared by insertion of a consensus binding sequence for wild type
U1 snRNA in the 30 untranslated region (30UTR) of luciferase coding
sequence. This luciferase expression plasmid was represented as
WTx1. In addition to the wild type sequence, plasmid containing
a mutated U1 binding sequence was also prepared, which was rep-
resented as MTx1. Moreover, the U1snRNA binding sequence (or
mutated U1snRNA binding sequence) was inserted in tandem to
give WTx2 and WTx3 (and also MTx2 and MTx3) to show the re-
quired U1i activity more vividly.7,9,20 Since the resulting pre-
mRNAs from a series of WT plasmids have wild-type U1snRNP
binding sequence, the luciferase activity is expected to decrease
compared with control plasmid (pGL3-C without the U1snRNA
binding sequence) arising from the desired U1i activity. On the
other hand, the luciferase activity should be active upon transfec-
tion of a series of MT plasmids, because endogenous U1snRNP can-
not bind to the resulting pre-mRNAs. After the desired plasmids
were prepared, the function of the resulting plasmids was ﬁrstly
tested. The luciferase activity after 24 h upon transfection of
pGL3-C into HeLa cells was set as 100%, and relative activity of each
plasmid was evaluated. As can be seen in Figure 3, the luciferase
activity was reduced to approximately 40% when WTx1 plasmid
was transfected into HeLa cells. The activity was completely lost
when WTx2 and WTx3 plasmids were transfected. On the other
hand, little gene suppression was observed upon transfection of
MTx1, MTx2, or MTx3, since the endogenous U1snRNP cannot bind
to the resulting pre-mRNAs from a series of MT plasmids. These re-
sults conﬁrmed that the reporter assay system to evaluate U1i
activity was successfully constructed.
As described in Section 1, Goraczniak et al. reported induction
of U1i using U1 adaptors, which recruite U1snRNP on the target(A) (B)
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Figure 1. Structures of 20-modiﬁed-40-thioRNAs.pre-mRNA (Fig. 2B).9 In their report, they carefully investigated
the relationship between modiﬁcation pattern of U1 adaptor and
U1i activity. As a result, the adaptor ONs modiﬁed with uniform
20-OMeRNA showed no U1i activity, while those containing
20-OMeRNA and LNA, which would exhibit higher hybridization
ability with complementary RNA, induced effective U1i. In addi-
tion, the best activity was obtained in U1 adaptor consisting of
15 mer of the target domain and 13 mer of the U1 domain. With
these previous studies as references, we designed U1 adaptors con-
taining various chemically-modiﬁed nucleoside units including
20-modiﬁed-40-thionucleosides. The sequence and modiﬁcation
pattern of the U1 adaptors are shown in Figure 4A. The adaptors
are all 28 mer and consist of the target domain (50-AAGCUUG-
CUCGCAAC-30) and the U1 domain (50-GCCAGGUAAGUAU-30). To
append higher hybridization ability, purine units of U1 adaptors
were all modiﬁed with 20-ﬂuoronucleoside (20-F) units. On the
other hand, pyrimidine units were modiﬁed with 20-F, 20-OMe,
20-OMe-40-thio, or 20-F-40-thio nucleoside units to give adaptors
1–4. From the data shown in Figure 3, the plasmid possessing mul-
tiple binding sites, that is, MTx3 seemed better to evaluate U1i
activity by the adaptor ONs. Thus, each of adaptors 1–4 was
cotransfected with MTx3 plasmid into HeLa cells, and the activity
of gene suppression relative to that of 40 nM of T7 terminator se-
quence as a negative control was evaluated after 24 h. As shown in
Table 1
Hybridization ability of adaptors with RNA1 or RNA2
(A) Tm values of duplex between the target domain of each adaptor and a complementary RNA1 (15 mer). (B) Tm values of duplex between the U1 domain of each adaptor and
a complementary RNA2 (13 mer).
a Tm values were given as an average of three independent experiments.
b Tm values were calculated based on the Tm values of RNA:RNA1 or RNA:RNA2.
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40-thio/20-F21 units, did not shown any signiﬁcant gene suppres-
sion, although slight activity was observed at higher concentration
(40 nM). Contrary to adaptors 1 and 3, the desired gene suppres-
sion dependent on the concentration of adaptor transfected was
obviously observed in adaptors 2 and 4, which consisted of 20-F/
20-F21 and 20-F-40-thio/20-F21 units. The IC50 value of adaptor 4
was estimated as 9.6 nM, which was almost equal to that of adap-
tor 2 (IC50 = 6.7 nM). In addition, these activities were almost com-
parable to the results reported by Goraczniak et al.9
To consider the difference of gene suppression activity by
adaptors 1–4, we measured Tm value of the duplexes between
the adaptor and a complementary RNA sequence. Since the adapt-
ors consist of the target domain and the U1 domain, complemen-
tary RNA sequences, that is RNA1 (50-GUUGCGAGCAAGCUU-30;
complementary to the target domain) and RNA2 (50-AUACUUAC-Figure 4. U1i activity by adaptor ONs modiﬁed with 20-modiﬁed-40-thionucleo-
sides. (A) The sequence and modiﬁcation pattern of the U1 adaptors. 20-OMe units
are uppercase, 20-F units are lowercase, 20-OMe-40-thio units are bold uppercase,
and 20-F-40-thio units are underlined uppercase. (B) Measurement of the U1i
activity of adaptor ONs. Details were described in the Section 3.CUGGC-30; complementary to the U1 domain), were prepared
and Tm values of the resulting duplexes were measured (Table 1).
The duplex of RNA, a natural 28 mer possessing the same sequence
context as the adaptor ONs, and RNA1 showed Tm value of 73.8 C.
The Tm values of adaptors:RNA1 were all higher than that of
RNA:RNA1 (DTms were from 7.7 to 14.6 C). The same tendency
was observed in the duplexes of adaptors:RNA2 (DTms were from
6.9 to 12.7 C). In general, adaptor ONs consisting of 20-F/20-F and
20-F-40-thio/20-F units formed thermally more stable duplexes than
ONs consisting of 20-OMe/20-F and 20-OMe-40-thio/20-F units.
Concerning stability against nuclease digestion, 20-OMeRNA and
20-OMe-40-thioRNA were much more stable than 20-FRNA and 20-F-
40-thioRNA.17 Therefore, it is expected that ONs consisting of 20-
OMe/20-F and 20-OMe-40-thio/20-F units would be more stable
against nuclease digestion than those consisting of 20-F/20-F and
20-F-40-thio/20-F units. As one explanation of the results in Fig-
ure 4B, therefore, it can be concluded that higher thermal stability
of adaptors, rather than nuclease resistance, is required for effec-
tive gene suppression, at least in vitro.
By the way, the adaptors have complementary sequences
against pre-mRNA. Therefore, there is a possibility that the adaptor
ONs act as an antisense molecule to suppress gene expression, but
not as the U1 adaptor. To exclude this possibility, we prepared two
sequences, that is, ON1 corresponding to the target domain andFigure 5. Comparison of gene suppression by adaptor 2, ON1, and ON2. Details
were described in the Section 3.
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with 20-F/20-F units, and their activity was evaluated at 4, 12, and
40 nM, respectively. As can be seen in Figure 5, neither ON1 nor
ON2 showed any signiﬁcant gene suppression under the same con-
ditions different from adaptor 2. In addition, combined transfection
of ON1 and ON2 into HeLa cells also showed no activity. These re-
sults strongly suggested that the adaptor ONs require both the tar-
get domain and the U1 domain in the molecule to suppress gene
expression, and their activity comes from U1i, but not antisense
mechanism.
In conclusion, we examined the gene suppression via U1i
machinery using ONs modiﬁed with 20-modiﬁed-40-thionucleo-
sides. The effective gene suppression was observed in ONs consist-
ing of 20-F/20-F and 20-F-40-thio/20-F units, while those consisting of
20-OMe/20-F and 20-OMe-40-thio/20-F units did not show signiﬁcant
activity. Therefore, it was suggested that 20-F and 20-F-40-thio
modiﬁcation is available for the gene suppression via U1i machin-
ery. Contrary to the favorable results reported by us in this manu-
script, Vickers et al. have reported that gene silencing mediated by
U1 adaptor resulted in signiﬁcant off-target silencing arising from
sequestering of U1 snRNP.22 In their report, the authors concluded
that careful screening of U1 adaptor sequences is needed to mini-
mize U1 snRNP sequestration and establish maximal speciﬁcity.
Thus, further examination would be required to show the utility
of U1i mediated by U1 adaptor. Since targeting the same gene
either U1 adaptor or siRNA strongly enhances gene silencing,9
development of not only siRNA but also U1 adaptor by 20-modi-
ﬁed-40-thioRNAs should be attractive, and these are currently
underway.3. Experimental section
3.1. Synthesis of ONs
Support bound chemically modiﬁed ONs used in this study
were synthesized on an H-6 DNA/RNA synthesizer (Nihon Techno
Service) using the corresponding phosphoramidite units at a
0.2 lmol scale following the standard procedure described for oli-
goribonucleotides. Each of phosphoramidite units was used at con-
centration of 0.07 M in dry acetonitrile, and the coupling time was
extended to 12 min for each step. After completion of the synthe-
sis, the CPG support was treated with methanolic ammonia (satu-
rated at 0 C) at room temperature for 24 h. Then, the support was
ﬁltered off. The ﬁltrate was concentrated and the ON protected by
a DMTr group at the 50-end was puriﬁed on reversed-phase HPLC,
using a J’sphere ODS-M80 column (10  150 mm, YMC) with a lin-
ear gradient of acetonitrile (from 5% to 50%) in 0.1 N TEAA buffer
(pH 7.0). The residue was concentrated and treated with aqueous
acetic acid (70%) for 20 min at room temperature. The solution
was concentrated and the residue was puriﬁed on reversed-phase
HPLC, using a J’sphere ODS-M80 column (10  150 mm, YMC) with
a linear gradient of acetonitrile (from 5% to 25%) in 0.1 N TEAA buf-
fer (pH 7.0). The structure of each adaptor ON was conﬁrmed by
measurement of MALDI-TOF/MASS spectrometry on an ultraﬂex
TOF/TOF (Buruker Daltonics). Adaptor 1; calculated mass,
C280H341F15N108O177 P27, 9174.4 (MH); observed mass, 9174.0.
Adaptor 2; calculated mass, C267H302F28N108O164P27, 9016.1
(MH); observed mass, 9016.7. Adaptor 3; calculated mass,
C280H341F15N108O164P27S13, 9379.1 (MH); observed mass, 9379.5.
Adaptor 4; calculated mass, C267H302F28N108O151P27S13, 9223.8
(MH); observed mass, 9223.7. The structure of ON1 and ON2
was conﬁrmed by measurement of LRMS (ESI-TOF) on Waters
LCT Premier 2695. ON1;m/z calculated for [M3H]3 1586.2, found
1585.9. ON2; m/z calculated for [M4H]4 1045.9, found 1046.0.3.2. Construction of plasmids for reporter assay
As shown in Figure 2A, double strand DNA of consensus binding
sequence for wild type U1 snRNA was synthesized, digested with
NheI and XbaI, and inserted into XbaI site located on the 30 UTR
of luciferase coding sequence of pGL3-C (Promega). The resulting
plasmid was termed WTx1. To prepare WTx2, WTx1 was digested
with XbaI and inserted above wild type U1 snRNA binding se-
quence. Using WTx2, WTx3 was also constructed. Similarly, by
using mutated U1 snRNA binding sequence, a series of MT plas-
mids (MTx1, MTx2, and MTx3) were also prepared.3.3. Evaluation of U1i activity
HeLa cells were cultured in Minimum Essential Medium con-
taining 10% fetal bovine serum with 1% non-essential amino acids.
About 3.5  105 cells were plated onto one well of 6-well culture
plate. For plasmid transfection (Figs. 3–5), each WT or MT reporter
plasmid (0.15 lg) was mixed with 0.6 lg of pRL-TK Renilla lucifer-
ase expression plasmid (Promega) to compensate transfection efﬁ-
ciency. Then, the combined plasmids were then transfected into
cells using X-treme GENE HP (Roche) 12 h after plating. For adapter
ONs transfection (Figs. 4 and 5), each adaptor was mixed with inef-
fective ON (T7 terminator sequence, 50-GCCTCTAAACGGGTCTT-
GAGG-30) to maintain the ON concentration at 40 nM
(100 pmols/2.5 mL culture medium). The combined ONs were then
transfected into cells using Lipofectamine 2000 (Invitrogen) 6 h be-
fore plasmid transfection. Twenty-four hour after plasmid trans-
fection, cell lysates were prepared and ﬁreﬂy and Renilla
luciferase activities were obtained by Inﬁnite 200 PRO (TECAN)
using Dual-Luciferase Reporter Assay System (Promega) according
to supplier’s recommendation. All the transfection experiments
were carried out three independent culture wells, and each ﬁreﬂy
luciferase activity was normalized to Renilla luciferase activity.
3.4. Measurement of Tm values
Thermally induced transitions were monitored at 260 nm on a
Shimazu UV-1800 Spectrophotometer. Samples were prepared as
follows. Duplex formation: a solution containing an appropriate
ON and a complementary sequence (1.5 lM each) in a buffer of
10 mM Na cacodylate (pH 7.0) containing 100 mM NaCl were
heated at 90 C for 3 min, then cooled gradually to room tempera-
ture and used for the thermal denaturation study. The sample tem-
perature was increased 1.0 C/min.
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